Article
A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma.
Cell reports - 23 Dec 2025
Zhang Yuntian, Urquijo Marcus A, Zitnay Rebecca G, Marks Kayla, Belote Rachel L, Hansen Maike M K, Ferita Montana, Neuendorf Hannah M, Liu Tong, Smith Eric A, Mehrabad Elnaz Mirzaei, Hejna Miroslav, Moustafa Tarek E, Lange Devin, Hu Min, Vand-Rajabpour Fatemeh, Done Anne, Becker Carly A, Lieberman Matthew, Chang Matthew, Lohman Brian K, Stubben Chris J, Reeves Melissa Q, Zhang Xiaoyang, Weinberger Leor S, VanBrocklin Matthew W, Deacon Dekker C, Grossman Douglas, Spike Benjamin T, Lex Alexander, Boyle Glen M, Kulkarni Rajan, Zangle Thomas A, Judson-Torres Robert L
Abstract excerpt
Metastatic spread and therapeutic resistance are the principal causes of cancer mortality. For melanoma, these processes rely on the capacity of cells to switch between transcriptional states. Although targeting transcriptional states pharmacologically is promising, the mechanisms by which melanoma cells switch between states-and how these processes differ from melanocytes-remain poorly understood. Here, we...
Read the complete abstract on PubMedTopics
- Melanoma
- Humans
- Proto-Oncogene Proteins c-myc